◎ Sugi Atlas

Atlas / Drug / Endostatin, N-Terminal-Mggshhhhh

Endostatin, N-Terminal-Mggshhhhh

drug
On this page

Also known as EndostarEndostatinn-terminal-mggshhhhhN-terminal-mggshhhhh-endostatin

Summary

Endostatin, N-Terminal-Mggshhhhh (CHEMBL4297946) is a phase-3 clinical-stage unknown; indicated across 23 conditions including cervical carcinoma and non-small cell lung carcinoma.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Unknown
  • Indications: 23 conditions
  • Clinical trials: 55

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL4297946
NameEndostatin, N-Terminal-Mggshhhhh
TypeUnknown
Max phase3

Also known as: Endostar, Endostatin, n-terminal-mggshhhhh, N-terminal-mggshhhhh-endostatin, ENDOSTATIN, N-TERMINAL-MGGSHHHHH

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

23 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
cervical carcinoma3MONDO:0005131EFO:0001061
non-small cell lung carcinoma3MONDO:0005233EFO:0003060
gastric neoplasm3MONDO:0021085MONDO:0001056
breast neoplasm3MONDO:0021100MONDO:0007254
lung neoplasm3MONDO:0021117MONDO:0008903
nasopharyngeal carcinoma3MONDO:0015459MONDO:0015459
peripheral T-cell lymphoma, not otherwise specified2MONDO:0004964EFO:0000211
neuroblastoma2MONDO:0005072EFO:0000621
osteosarcoma2MONDO:0009807EFO:0000637
small cell lung carcinoma2MONDO:0008433EFO:0000702
nasopharyngeal neoplasm2MONDO:0005375EFO:0004252
esophageal squamous cell carcinoma2MONDO:0005580EFO:0005922
soft tissue sarcoma2MONDO:0018078EFO:1001968
hepatocellular carcinoma2MONDO:0007256EFO:0000182
lymphoma2MONDO:0005062EFO:0000574
thrombotic disease2MONDO:0000831MONDO:0000831
cutaneous melanoma2MONDO:0005012EFO:0000389
malignant pancreatic neoplasm2MONDO:0009831EFO:1000359
neoplasm2MONDO:0005070EFO:0000616
colorectal neoplasm2MONDO:0005335MONDO:0005575

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 55.

Phase distribution

PhaseTrials
PHASE242
PHASE44
PHASE34
PHASE13
Not specified2

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01028729PHASE4UNKNOWNA Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC)
NCT02513342PHASE4UNKNOWNEndostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma
NCT02513355PHASE4UNKNOWNEndostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research
NCT04164797PHASE4UNKNOWNStudy of Endostar Combined With TP Regimen for Esophageal Cancer
NCT02008422PHASE3UNKNOWNClinical Study of Endostar Injection Concomitant With SOX Protocols to Treat Advanced Gastric Cancer
NCT02579564PHASE3UNKNOWNSystemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients
NCT02865304PHASE3UNKNOWNThe Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative MBC Patients
NCT02907710PHASE3UNKNOWNEndostar Combined With Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma
NCT06055816PHASE2RECRUITINGGemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma
NCT00842491PHASE2COMPLETEDStudy of Endostar With Cisplatin and Capecitabine as 1st Line Treatment in the Advanced Gastric Cancer
NCT00853684PHASE2UNKNOWNOxaliplatin, Capecitabine and Endostar as First Line Treatment for Patients With Advanced Colorectal Cancer
NCT00912392PHASE2COMPLETEDEtoposide-Carboplatin Alone or With Endostar for Extensive Disease Small Cell Lung Cancer (ED-SCLC)
NCT00974324PHASE2UNKNOWNEndostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma
NCT01002092PHASE2UNKNOWNA Study of Endostar Combined With Chemotherapy for Treatment of Osteosarcoma
NCT01158144PHASE2UNKNOWNConcurrent Endostar, Paclitaxel/Carboplatin and Radiotherapy for Locally Advanced Non-small Cell Lung (RT0902)
NCT01327235PHASE2COMPLETEDEndostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites
NCT01368419PHASE2UNKNOWNContinuous Endostar Infusion Combined With Radiotherapy in Esophageal Cancer Patients
NCT01410370PHASE2UNKNOWNContinuous Endostar Infusion Combined With Radiotherapy in Patients With Brain Metastases
NCT01430013PHASE2UNKNOWNTrial of Endostar Combined With CHOPT for T Cell Lymphoma
NCT01549093PHASE2UNKNOWNEndostar Continued Pumping Into Vein Combining With Gemcitabine-Carboplatin to Treat Non-Small Cell Lung Cancer (NSCLC)
NCT01564329PHASE2UNKNOWNThe Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar
NCT01687439PHASE2COMPLETEDEffect of Endostar Combined With Chemotherapy and Radiotherapy on Blood Vessels and Microenvironment of Tumor for Non-small Cell Lung Cancer (NSCLC)
NCT01812018PHASE2UNKNOWNEndostar + GT in Pulmonary Metastases of Soft Tissue Sarcoma
NCT01832948PHASE2UNKNOWNEndostar Combined With mFOLFOX6 for First-line Treatment of Metastatic Colorectal Cancer
NCT02237924PHASE2COMPLETEDEndostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma
NCT02350517PHASE2COMPLETEDEndostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal Cancer
NCT02375022PHASE2UNKNOWNRh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations
NCT02444949PHASE2COMPLETEDA Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma
NCT02520219PHASE2UNKNOWNEndostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study
NCT02615106PHASE2UNKNOWNAnti-angiogenetic Therapy With Radiotherapy for Pediatric Neuroblastoma
NCT02665702PHASE2UNKNOWNEndostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas
NCT02749526PHASE2TERMINATEDEndostar Combined With MPFC Adjuvant Treatment of Esophageal Cancer Clinical Trial
NCT02902432PHASE2UNKNOWNA Trial of Endostar in Patients With Carcinoma of the Head and Neck
NCT03086681PHASE2COMPLETEDEndostar Combined With Concurrent Chemoradiotherapy For Locally Advanced Cervical Carcinoma
NCT03121833PHASE2COMPLETEDEndostar Combined With Chemotherapy for Stage Ⅳ Soft Tissue Sarcoma
NCT03123445PHASE2UNKNOWNEndostar First-line Treatment of Advanced NSCLC
NCT03614065PHASE2UNKNOWNEndostar Combine With Radiotherapy in Brain Metastasis of NSCLC
NCT03622827PHASE2UNKNOWNPostoperative Concurrent Chemoradiotherapy Combined With Endostar for High-risk Early Stage Cervical Cancer
NCT03649945PHASE2UNKNOWNEndostatin Combined With Chemotherapy for Adjuvant Treatment of Esophageal Cancer
NCT03706703PHASE2UNKNOWNRh-Endostatin (Endostar®) Continuous Intravenous Infusion

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 14

This page pulls from 14 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclinical_trialsefogtopdb_ligandmeshmondopatent_compoundpharmgkbpharmgkb_guidelinepubchem